🇺🇸 FDA
Pipeline program

Zasocitinib (Dose A)

TAK-279-HS-2001

Phase 2 small_molecule active

Quick answer

Zasocitinib (Dose A) for Hidradenitis Suppurativa is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Hidradenitis Suppurativa
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials